Pharmacological agents targeting NET formation, such as PAD4 inhibitors, demonstrate significantly enhanced efficacy in attenuating AAA progression in experimental models possessing an ILT [27, 31]. This evidence concerns the gene PADI4 and triple-A syndrome.